Gotham Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Gotham Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13,702	Closed	-$459K	–	1879
2026 Q1	$459K	Buy	13,702 +1,572	+13%	+$61.6K	﹤0.01%	1510
2025 Q4	$562K	Buy	+12,130	New	+$665K	﹤0.01%	1408

Gotham Asset Management's SLNO Position: Q2 2026 in Review

Gotham Asset Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 13,702 shares — an estimated $459K sold.

Gotham Asset Management first reported a position in SLNO in Q4 2025 and held it in 2 quarters. The position peaked at $562K in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Gotham Asset Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Gotham Asset Management sold 13,702 Soleno Therapeutics shares in Q2 2026, an estimated $459K.
Gotham Asset Management first reported a position in Soleno Therapeutics in Q4 2025 and held it in 2 quarters.
Gotham Asset Management's Soleno Therapeutics position peaked at $562K in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.